// App-Quantinova.ai

e13024 : Killer-cell Inmunoglobulin-like Receptor (KIR) genes as a predictor of response to the anti-HER therapy in solid tumors.

Researchers

Presenter

  • Cristina Morales-Estevez

Principal Investigators

  • Barbara Manzanares-Martin

  • Juan de la Haba-Rodriguez

  • Rafael Gonzalez-Fernandez

  • Javier Lopez-Gonzalez

  • Alberto Moreno

  • Ignacio Porras

  • Maria Jose Ortiz

  • Maria Auxiliadora Gomez-Espana

  • Maria Teresa Cano

  • Beatriz Chia-Delgado

  • Raquel Serrano

  • M Jesus Rubio

  • Enrique Aranda

Medical Centers

  • Pathological Anatomy Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain

  • Pathological Anatomy Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, Spain

  • Medical Oncology Department University Reina Sofia Hospital. Biomedical Research Institute Maimonides, Cordoba, Spain

  • University Hospital Reina Sofia, Cordoba, Spain

  • Hospital Universitario Reina Sofia, Cordoba, Spain

  • Reina Sofia Hospital, University of Cordoba, Maimonides Institute of Biomedical Research (IMIBIC). Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Cordoba, Spain

  • Department of Clinical Oncology, Hospital Reina Sofia, Cordoba, Spain

  • Reina Sofia Hospital, University of Cordoba, Maimonides Institute of Biomedical Research (IMIBIC). Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Cordoba, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Epidermal growth factor receptor

  • Major Histocompatibility Complex, Class I, B

Drug/Treatment

  • Trastuzumab

  • Erbitux

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final